» Articles » PMID: 20150305

Onset and Progression of Pathologic Atrophy in Huntington Disease: a Longitudinal MR Imaging Study

Overview
Specialty Neurology
Date 2010 Feb 13
PMID 20150305
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease.

Materials And Methods: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age.

Results: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02).

Conclusions: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.

Citing Articles

Brain Volumetric Analysis Using Artificial Intelligence Software in Premanifest Huntington's Disease Individuals from a Colombian Caribbean Population.

Rios-Anillo M, Ahmad M, Acosta-Lopez J, Cervantes-Henriquez M, Henao-Castano M, Morales-Moreno M Biomedicines. 2024; 12(10).

PMID: 39457479 PMC: 11504451. DOI: 10.3390/biomedicines12102166.


Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington's Disease: A Review of Data from Mouse Models.

Hanrahan J, Locke D, Cahill L J Huntingtons Dis. 2024; 13(3):279-299.

PMID: 39213087 PMC: 11494634. DOI: 10.3233/JHD-240045.


Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.

Hobbs N, Papoutsi M, Delva A, Kinnunen K, Nakajima M, Van Laere K J Huntingtons Dis. 2024; 13(2):163-199.

PMID: 38788082 PMC: 11307036. DOI: 10.3233/JHD-240016.


Optimizing Screening for Intrastriatal Interventions in Huntington's Disease Using Predictive Models.

Barrett M, Negida A, Mukhopadhyay N, Kim J, Nawaz H, Jose J Mov Disord. 2024; 39(5):855-862.

PMID: 38465778 PMC: 11102310. DOI: 10.1002/mds.29749.


Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.

Wilton D, Mastro K, Heller M, Gergits F, Willing C, Fahey J Nat Med. 2023; 29(11):2866-2884.

PMID: 37814059 PMC: 10667107. DOI: 10.1038/s41591-023-02566-3.


References
1.
Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L . Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. DOI: 10.1212/01.WNL.0000159743.08996.99. View

2.
Paulsen J, Hayden M, Stout J, Langbehn D, Aylward E, Ross C . Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006; 63(6):883-90. DOI: 10.1001/archneur.63.6.883. View

3.
Henley S, Wild E, Hobbs N, Warren J, Frost C, Scahill R . Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia. 2008; 46(8):2152-60. DOI: 10.1016/j.neuropsychologia.2008.02.025. View

4.
Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4):267-77. DOI: 10.1111/j.1399-0004.2004.00241.x. View

5.
Henley S, Wild E, Hobbs N, Frost C, MacManus D, Barker R . Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord. 2009; 24(6):932-6. DOI: 10.1002/mds.22485. View